These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10533471)

  • 1. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK).
    Bernhard J; Castiglione-Gertsch M; Schmitz SF; Thürlimann B; Cavalli F; Morant R; Fey MF; Bonnefoi H; Goldhirsch A; Hürny C
    Eur J Cancer; 1999 Jun; 35(6):913-20. PubMed ID: 10533471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
    Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
    Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
    Bernhard J; Thürlimann B; Schmitz SF; Castiglione-Gertsch M; Cavalli F; Morant R; Fey MF; Bonnefoi H; Goldhirsch A; Hürny C
    J Clin Oncol; 1999 Jun; 17(6):1672-9. PubMed ID: 10561203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
    Wiseman LR; Goa KL
    Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
    Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
    Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer.
    Stuart NS; Warwick J; Blackledge GR; Spooner D; Keen C; Taylor AR; Tyrell C; Webster DJ; Earl H
    Eur J Cancer; 1996 Oct; 32A(11):1888-92. PubMed ID: 8943670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
    Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Zilembo N; Dugardyn JL; Nasurdi C; Mennel RG; Cervek J; Fowst C; Polli A; di Salle E; Arkhipov A; Piscitelli G; Miller LL; Massimini G
    J Clin Oncol; 2000 Apr; 18(7):1399-411. PubMed ID: 10735887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
    Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
    Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
    J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen.
    Freue M; Kjaer M; Boni C; Joliver J; Jänicke F; Willemse PH; Coombes RC; Van Belle S; Pérez-Carrión R; Zieschang J; Ibarra de Palacios P; Rose C
    Breast; 2000 Feb; 9(1):9-16. PubMed ID: 14731578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
    Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L
    Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
    Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
    J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
    Goss PE; Winer EP; Tannock IF; Schwartz LH
    J Clin Oncol; 1999 Jan; 17(1):52-63. PubMed ID: 10458218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response.
    Ettinger DS; Allegra J; Bertino JR; Bonomi P; Browder H; Byrne P; Carpenter J; Catalano R; Creech R; Dana B
    Semin Oncol; 1986 Dec; 13(4 Suppl 4):9-14. PubMed ID: 3026052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial.
    Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Cervek J; Fowst C; Polli A; Di Salle E; Massimini G; Piscitelli G
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S86-7. PubMed ID: 11056333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formestane in the treatment of advanced postmenopausal breast cancer.
    Possinger K; Jonat W; Höffken K
    Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced breast cancer with formestane.
    Murray R; Pitt P
    Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
    Bajetta E; Zilembo N; Barni S; Noberasco C; Martinetti A; Ferrari L; Schieppati G; Buzzoni R; Jirillo A; Amichetti M; D'Aprile M; Comella G; Bichisao E; Bolelli GF; Attili A; Bombardieri E
    Ann Oncol; 1997 Jul; 8(7):649-54. PubMed ID: 9296217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group.
    Hürny C; Bernhard J; Coates AS; Castiglione-Gertsch M; Peterson HF; Gelber RD; Forbes JF; Rudenstam CM; Simoncini E; Crivellari D; Goldhirsch A; Senn HJ
    Lancet; 1996 May; 347(9011):1279-84. PubMed ID: 8622502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer.
    Paterson AH; Hanson J; Pritchard KI; Sansregret E; Dahrouge S; McDermot RS; Fine S; White DF; Trudeau M; Stewart DJ
    Semin Oncol; 1990 Dec; 17(6 Suppl 9):52-62. PubMed ID: 2259927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.